These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 21402292)

  • 61. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-Term Cost Analysis of Third-Line Treatment Options for Overactive Bladder.
    Pelling M; Hammett J; Patil D
    Urol Pract; 2024 Jan; 11(1):62-69. PubMed ID: 37916945
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?
    Marcelissen T; Cornu JN; Antunes-Lopes T; Geavlete B; Delongchamps NB; Rashid T; Rieken M; Rahnama'i MS
    Eur Urol Focus; 2018 Sep; 4(5):760-767. PubMed ID: 29807823
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
    Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
    J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost.
    Chughtai B; Clemens JQ; Thomas D; Sun T; Ghomrawi H; Sedrakyan A
    J Urol; 2020 Jan; 203(1):179-184. PubMed ID: 31347949
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment for refractory overactive bladder: a systematic review and meta-analysis of sacral neuromodulation and onabotulinumtoxinA.
    He Q; Li B; Zhang C; Zhang J; Luo D; Wang K
    Int Urogynecol J; 2021 Mar; 32(3):477-484. PubMed ID: 32661556
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Women's perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment.
    Balchandra P; Rogerson L
    Int Urogynecol J; 2014 Aug; 25(8):1059-64. PubMed ID: 24633067
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
    Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
    J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The value of urodynamic tools to guide patient selection in sacral neuromodulation.
    Drossaerts J; Rademakers K; van Koeveringe G; Van Kerrebroeck P
    World J Urol; 2015 Nov; 33(11):1889-95. PubMed ID: 25680936
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The role of neuromodulation in patients with neurogenic overactive bladder.
    Lay AH; Das AK
    Curr Urol Rep; 2012 Oct; 13(5):343-7. PubMed ID: 22865208
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sacral Neuromodulation with the InterStim™ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
    Chartier-Kastler E; Le Normand L; Ruffion A; Dargent F; Braguet R; Saussine C; Tanneau Y; Graziana JP; Ragni E; Rabut B; Rousseau T; Biardeau X; Gamé X; Pierrevelcin J; Brassart E; Fourmarier M; Stoica G; Berrogain N; Yaghi N; Pecoux F; Capon G; Ferchaud J; Peyrat L; Bryckaert PE; Karsenty G; Melotti A; Abouihia A; Keller DUJ; Cornu JN
    Eur Urol Focus; 2021 Nov; 7(6):1430-1437. PubMed ID: 32907782
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An overview of sacral neuromodulation: a treatment for patients with symptoms of lower urinary tract dysfunction.
    Fletcher N
    Br J Nurs; 2020 Aug; 29(15):848-856. PubMed ID: 32790556
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction.
    Cohn JA; Kowalik CG; Kaufman MR; Reynolds WS; Milam DF; Dmochowski RR
    Expert Rev Med Devices; 2017 Jan; 14(1):3-14. PubMed ID: 27915486
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol.
    Rahnama'i MS; Marcelissen T; Apostolidis A; Veit-Rubin N; Schurch B; Cardozo L; Dmochowski R
    Neurourol Urodyn; 2018 Jun; 37(S4):S99-S107. PubMed ID: 29363792
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Trends and Clinical Practice Patterns of Sacral Neuromodulation for Overactive Bladder.
    Elterman DS; Chughtai B; Vertosick E; Thomas D; Eastham J; Sandhu J
    Female Pelvic Med Reconstr Surg; 2018; 24(4):264-266. PubMed ID: 28658001
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy.
    Leong RK; De Wachter SG; Nieman FH; de Bie RA; van Kerrebroeck PE
    Neurourol Urodyn; 2011 Sep; 30(7):1249-52. PubMed ID: 21404317
    [TBL] [Abstract][Full Text] [Related]  

  • 77. How can we better manage drug-resistant OAB/DO? ICI-RS 2018.
    Chermansky C; Schurch B; Rahnama'i MS; Averbeck MA; Malde S; Mancini V; Valentini F; Sahai A
    Neurourol Urodyn; 2019 Dec; 38 Suppl 5():S46-S55. PubMed ID: 31821628
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sensing in Sacral Neuromodulation: A Feasibility Study in Subjects With Urinary Incontinence and Retention.
    Goudelocke C; Jungbauer Nikolas LM; Bittner KC; Offutt SJ; Miller AE; Slopsema JP
    Neuromodulation; 2024 Feb; 27(2):392-398. PubMed ID: 37589643
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Results of sacral nerve modulation for treatment of overactive bladder].
    Braun PM; Böhler G
    Urologe A; 2006 Jul; 45(7):835-40. PubMed ID: 16773383
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique.
    Adelstein SA; Lee W; Gioia K; Moskowitz D; Stamnes K; Lucioni A; Kobashi KC; Lee UJ
    Neurourol Urodyn; 2019 Aug; 38(6):1595-1601. PubMed ID: 31044466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.